TY - JOUR
T1 - Iron Overload Exacerbates Busulfan-Melphalan Toxicity Through a Pharmacodynamic Interaction in Mice
AU - Bouligand, Jérôme
AU - Richard, Clémentine
AU - Valteau-Couanet, Dominique
AU - Orear, Cedric
AU - Mercier, Lionel
AU - Kessari, Romain
AU - Simonnard, Nicolas
AU - Munier, Fabienne
AU - Daudigeos-Dubus, Estelle
AU - Tou, Bassim
AU - Opolon, Paule
AU - Deroussent, Alain
AU - Paci, Angelo
AU - Vassal, Gilles
N1 - Publisher Copyright:
© 2016, Springer Science+Business Media New York.
PY - 2016/8/1
Y1 - 2016/8/1
N2 - Purpose: Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level. Methods: We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice. Results: Iron excess dramatically increased the toxicity of melphalan or busulfan melphalan combination in mice but it did not modify the clearance of either busulfan or melphalan. We show that prior busulfan treatment impairs the clearance of melphalan. This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction. Additionally, iron overload increased melphalan toxicity without altering its pharmacokinetics, suggesting a pharmacodynamic interaction between iron and melphalan. Based on iron homeostasis disturbance, we postulated that prior induction of ferritin, through Nrf2 activation after oxidative stress, may be associated with the alteration of melphalan metabolism. Conclusion: Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan.
AB - Purpose: Busulfan-melphalan high-dose chemotherapy followed by autologous stem cell transplantation is an essential consolidation treatment of high-risk neuroblastoma in children. Main treatment limitation is hepatic veno-occlusive disease, the most severe and frequent extra-hematological toxicity. This life threatening toxicity has been related to a drug interaction between busulfan and melphalan which might be increased by prior disturbance of iron homeostasis, i.e. an increased plasma ferritin level. Methods: We performed an experimental study of busulfan and melphalan pharmacodynamic and pharmacokinetics in iron overloaded mice. Results: Iron excess dramatically increased the toxicity of melphalan or busulfan melphalan combination in mice but it did not modify the clearance of either busulfan or melphalan. We show that prior busulfan treatment impairs the clearance of melphalan. This clearance alteration was exacerbated in iron overloaded mice demonstrating a pharmacokinetic interaction. Additionally, iron overload increased melphalan toxicity without altering its pharmacokinetics, suggesting a pharmacodynamic interaction between iron and melphalan. Based on iron homeostasis disturbance, we postulated that prior induction of ferritin, through Nrf2 activation after oxidative stress, may be associated with the alteration of melphalan metabolism. Conclusion: Iron overload increases melphalan and busulfan-melphalan toxicity through a pharmacodynamic interaction and reveals a pharmacokinetic drug interaction between busulfan and melphalan.
KW - Nrf2
KW - bone marrow transplantation
KW - drug interaction
KW - glutathione
KW - metabolism
KW - mice
KW - pharmacodynamic
KW - pharmacokinetics
KW - toxicity
UR - http://www.scopus.com/inward/record.url?scp=84964318927&partnerID=8YFLogxK
U2 - 10.1007/s11095-016-1927-z
DO - 10.1007/s11095-016-1927-z
M3 - Article
C2 - 27091031
AN - SCOPUS:84964318927
SN - 0724-8741
VL - 33
SP - 1913
EP - 1922
JO - Pharmaceutical research
JF - Pharmaceutical research
IS - 8
ER -